Abiopharma

🔍 KENNEY CHRISTOPHER JOHN (Executive)

Company: Xenon Pharmaceuticals Inc. (XENE)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 7,500 shares of Common Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: false | shares_owned_after: 7,500.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 2,771 shares of Common Shares at $60.108 per share (Direct)
  Date: 2026-03-10 | Code: S | equity_swap_involved: false | shares_owned_after: 4,729.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 7,500 shares of Performance Share Units (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: false | shares_owned_after: 7,500.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 7,500 shares of Performance Share Units (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination.
• F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024.